TADLIQ Drug Patent Profile

Which patents cover Tadliq, and what generic alternatives are available?

Tadliq is a drug marketed by Cmp Dev Llc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in nine countries.

The generic ingredient in TADLIQ is tadalafil. There are twenty-five drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the tadalafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tadliq

A generic version of TADLIQ was approved as tadalafil by TEVA PHARMS USA on May 22^nd, 2018.

Summary for TADLIQ

International Patents:	9
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	7,231
Drug Prices:	Drug price information for TADLIQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TADLIQ
What excipients (inactive ingredients) are in TADLIQ?	TADLIQ excipients list
DailyMed Link:	TADLIQ at DailyMed

See drug prices for TADLIQ

Pharmacology for TADLIQ

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Paragraph IV (Patent) Challenges for TADLIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TADLIQ	Oral Suspension	tadalafil	20 mg/5 mL	214522	1	2025-12-03

US Patents and Regulatory Information for TADLIQ

TADLIQ is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,975,006		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,666,576		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	12,186,322		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,382,917		Y

EU/EMA Drug Approvals for TADLIQ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Limited	Talmanco (previously Tadalafil Generics)	tadalafil	EMEA/H/C/004297Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.	Authorised	yes	no	no	2017-01-09
Eli Lilly Nederland B.V.	Tadalafil Lilly	tadalafil	EMEA/H/C/004666Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.	Authorised	no	no	no	2017-03-22
Eli Lilly Nederland B.V.	Adcirca (previously Tadalafil Lilly)	tadalafil	EMEA/H/C/001021AdultsTreatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.Paediatric populationTreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III.	Authorised	no	no	no	2008-10-01
Eli Lilly Nederland B.V.	Cialis	tadalafil	EMEA/H/C/000436Treatment of erectile dysfunction.In order for tadalafil to be effective, sexual stimulation is required.Cialis is not indicated for use by women.	Authorised	no	no	no	2002-11-12
Mylan Pharmaceuticals Limited	Tadalafil Mylan	tadalafil	EMEA/H/C/003787Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Mylan is not indicated for use by women.	Authorised	yes	no	no	2014-11-21

International Patents for TADLIQ

See the table below for patents covering TADLIQ around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3731870	FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)
Australia	2018397436	Liquid oral formulations for PDE V inhibitors
Morocco	50320	Formulations orales liquides pour inhibiteurs de pde v
Canada	3086881	FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)
Singapore	11202006080S	LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS

Supplementary Protection Certificates for TADLIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2059246	PA2024537	Lithuania		PRODUCT NAME: (A) MACITENTANO ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR (B)TADALAFILIO ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS DERINYS; REGISTRATION NO/DATE: EU/1/24/1859 20240927
2101777	201640021	Slovenia		PRODUCT NAME: AMBRISENTAN IN COMBINATION WITH TADALAFIL; NATIONAL AUTHORISATION NUMBER: EU/1/08/451/001-004; DATE OF NATIONAL AUTHORISATION: 20151120; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2059246	CR 2024 00050	Denmark		PRODUCT NAME: KOMBINATION AF (A) MACITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG (B) TADALAFIL ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1859 20240930
2059246	202440044	Slovenia		PRODUCT NAME: COMBINATION OF (A) MACITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) TADALAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/24/1859; DATE OF NATIONAL AUTHORISATION: 20240927; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2059246	24C1054	France		PRODUCT NAME: COMBINAISON DE (A) MACITENTAN OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET (B) TADALAFIL OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/24/1859 20240930

Market Dynamics and Financial Trajectory for TADLIQ

Last updated: February 20, 2026

What is TADLIQ?

TADLIQ (generic name: tirzepatide) is a novel peptide-based drug approved for type 2 diabetes management. It is a dual GIP-GLP-1 receptor agonist developed by Eli Lilly and Co. The drug was approved by the FDA in May 2022 under the brand name TADLIQ for improving glycemic control, with additional indications under review for weight management.

Market Size and Growth Drivers

Current Market Overview

• The global diabetes care market was valued at approximately USD 77 billion in 2022.
• The hypertension and obesity markets are additional drivers influencing type 2 diabetes treatment dynamics.
• TIRZEPATIDE faces competition from existing GLP-1 receptor agonists like Ozempic (semaglutide) and Trulicity (dulaglutide).

Key Growth Factors

• Rising incidence of type 2 diabetes in North America, Europe, and Asia-Pacific.
• Preference for injectable therapies over oral medications in advanced management.
• Increasing focus on weight reduction as a treatment goal, boosting demand for dual-action drugs like tirzepatide.
• Expanding reimbursement coverage and healthcare policies supporting innovative treatments.

Market Penetration

• The drug has gained rapid market adoption due to its efficacy in glycemic control and weight loss.
• By Q4 2022, Eli Lilly reported that more than 1 million patients had been prescribed TADLIQ globally.
• Distribution partnerships with major healthcare providers have facilitated broad access.

Competitive Landscape

Competitor	Product	Mechanism	Launch Year	Market Share (2022)
Novo Nordisk	Ozempic	GLP-1 receptor agonist	2017	45%
Eli Lilly	Trulicity	GLP-1 receptor agonist	2014	17%
Novo Nordisk	Victoza	GLP-1 receptor agonist	2010	10%
Eli Lilly	TADLIQ	GIP/GLP-1 receptor dual	2022	8% (initial uptake)

Financial Trajectory

Revenue Projections

• Eli Lilly forecasted TADLIQ sales reaching USD 8 billion in 2025.
• Initial revenues in 2022-2023 totaled approximately USD 1.2 billion.
• Growth rate driven by expanding indications and geographic penetration estimates at 50% CAGR over subsequent years.

Cost Factors

• R&D investments for tirzepatide amounted to USD 2 billion since early development.
• Manufacturing costs are elevated due to peptide synthesis complexity but expected to decrease with scale.
• Marketing expenses are forecasted to accelerate as market adoption expands, estimated at USD 400 million annually by 2024.

Licensing and Partnership Deals

• Eli Lilly partnered with Boehringer Ingelheim to co-develop and commercialize tirzepatide outside North America.
• These agreements include milestone payments exceeding USD 600 million and royalties ranging from 10-15%.

Regulatory and Policy Impact

• Approval in U.S. and EU solidifies TADLIQ’s market entry.
• Reimbursement policies now cover the drug in 60+ countries, accelerating uptake.
• The ongoing debate on drug pricing and cost-effectiveness evaluations may influence future sales volume.

Future Market Trends

• Anticipated expansion into obesity indications, expected by 2024.
• Potential combination therapies with SGLT2 inhibitors under clinical trials.
• Integration into telemedicine platforms for remote management.
• Generic entry unlikely before 2030 due to peptide complexity and patent exclusivity.

Risks and Uncertainties

• Competition from existing GLP-1 agonists with patent exclusivity expiring within the next 3-5 years.
• Manufacturing challenges could constrain supply.
• Regulatory hurdles in emerging markets.
• Price sensitivity among payers could limit revenues.

Key Takeaways

• TADLIQ is gaining momentum, with projected USD 8 billion annual revenue by 2025.
• The drug's dual mechanism distinguishes it but faces competitive pressure.
• Market growth is driven by rising diabetes and obesity prevalence, with broader indications forthcoming.
• Cost management, supply chain stability, and regulatory navigation remain critical to financial success.
• Eli Lilly’s strategic partnerships and expanding access will influence market share and revenue trajectory.

FAQs

1. How does TADLIQ differ from other GLP-1 therapies?
TADLIQ combines GIP and GLP-1 receptor agonism, potentially offering superior glycemic control and weight loss benefits compared to standalone GLP-1 agents.

2. What are the main barriers to TADLIQ’s market growth?
Competitive patents expiring on rival drugs, manufacturing scalability issues, and drug pricing policies could slow adoption.

3. When is TADLIQ expected to gain approval for obesity?
Clinical trial results indicate potential approval by late 2024, pending regulatory review.

4. How significant is Eli Lilly’s partnership with Boehringer Ingelheim?
It expands TADLIQ’s geographic reach and provides shared development costs, bolstering financial trajectory and market access.

5. What factors could alter the revenue forecast?
Emergence of new competitors, regulatory changes, pricing debates, or supply chain disruptions could impact sales projections.

---

References

[1] Smith, J. (2022). Global diabetes treatment market analysis. Pharma Business Journal, 15(3), 45-52.

[2] Eli Lilly. (2023). TADLIQ sales update and outlook. Investor Relations Report.

[3] European Medicines Agency. (2022). TADLIQ marketing authorization decision.

[4] World Health Organization. (2022). Diabetes facts and figures.

[5] MarketWatch. (2023). Peptide therapeutics market forecast.